Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarja Ikonen

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 18, 2007
Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and FinlandSuvi Torniainen, Maria Hedelin, Ville Autio, et al.
ESMO Open|December 2, 2020
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumoursPetri Bono, Christophe Massard, Katriina J Peltola, et al.
American Journal of Human Genetics|April 10, 2002
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancerAnnika Rökman, Tarja Ikonen, Eija H Seppälä, et al.
Bioorganic & Medicinal Chemistry|May 6, 2014
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacyRajeev Goswami, Subhendu Mukherjee, Chakshusmathi Ghadiyaram, et al.
European Journal of Human Genetics : EJHG|March 14, 2008
ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancerSanna Siltanen, Kirsi Syrjäkoski, Rainer Fagerholm, et al.
NEJM Evidence|February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate CancerKarim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
Human Genetics|November 19, 2004
Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locusAnnika Rökman, Agnes B Baffoe-Bonnie, Elizabeth Gillanders, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancerScott J Hebbring, Henna Fredriksson, Kirsten A White, et al.
Molecular Cancer Therapeutics|October 11, 2018
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor ImmunityTim H Holmström, Anu-Maarit Moilanen, Tarja Ikonen, et al.
Human Genetics|December 6, 2005
Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effectBao-Li Chang, Ethan M Lange, Latchezar Dimitrov, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 18, 2007
Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and FinlandSuvi Torniainen, Maria Hedelin, Ville Autio, et al.
ESMO Open|December 2, 2020
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumoursPetri Bono, Christophe Massard, Katriina J Peltola, et al.
American Journal of Human Genetics|April 10, 2002
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancerAnnika Rökman, Tarja Ikonen, Eija H Seppälä, et al.
Bioorganic & Medicinal Chemistry|May 6, 2014
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacyRajeev Goswami, Subhendu Mukherjee, Chakshusmathi Ghadiyaram, et al.
European Journal of Human Genetics : EJHG|March 14, 2008
ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancerSanna Siltanen, Kirsi Syrjäkoski, Rainer Fagerholm, et al.
NEJM Evidence|February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate CancerKarim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
Human Genetics|November 19, 2004
Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locusAnnika Rökman, Agnes B Baffoe-Bonnie, Elizabeth Gillanders, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancerScott J Hebbring, Henna Fredriksson, Kirsten A White, et al.
Molecular Cancer Therapeutics|October 11, 2018
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor ImmunityTim H Holmström, Anu-Maarit Moilanen, Tarja Ikonen, et al.
Human Genetics|December 6, 2005
Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effectBao-Li Chang, Ethan M Lange, Latchezar Dimitrov, et al.
Pageof 3